Publication:
Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.

Simple item page
dc.contributor.authorSalvador-Martin, Sara
dc.contributor.authorKaczmarczyk, Bartosz
dc.contributor.authorAlvarez, Rebeca
dc.contributor.authorNavas-Lopez, Victor Manuel
dc.contributor.authorGallego-Fernandez, Carmen
dc.contributor.authorMoreno-Alvarez, Ana
dc.contributor.authorSolar-Boga, Alfonso
dc.contributor.authorSanchez, Cesar
dc.contributor.authorTolin, Mar
dc.contributor.authorVelasco, Marta
dc.contributor.authorMuñoz-Codoceo, Rosana
dc.contributor.authorRodriguez-Martinez, Alejandro
dc.contributor.authorVayo, Concepcion A
dc.contributor.authorBossacoma, Ferran
dc.contributor.authorPujol-Muncunill, Gemma
dc.contributor.authorFobelo, Maria J
dc.contributor.authorMillan-Jimenez, Antonio
dc.contributor.authorMagallares, Lorena
dc.contributor.authorMartinez-Ojinaga, Eva
dc.contributor.authorLoverdos, Ines
dc.contributor.authorEizaguirre, Francisco J
dc.contributor.authorBlanca-Garcia, Jose A
dc.contributor.authorClemente, Susana
dc.contributor.authorGarcia-Romero, Ruth
dc.contributor.authorMerino-Bohorquez, Vicente
dc.contributor.authorGonzalez-de-Caldas, Rafael
dc.contributor.authorVazquez, Enrique
dc.contributor.authorDopazo, Ana
dc.contributor.authorSanjurjo-Saez, Maria
dc.contributor.authorLopez-Fernandez, Luis A
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderConsejería de Educación y Deporte de la Comunidad de Madrid
dc.contributor.funderGregorio Marañón Health Research Institute
dc.contributor.funderEuropean Regional Develompment Funds (FEDER) from the European Commission, “A way of making Europe”.
dc.date.accessioned2023-02-09T10:39:30Z
dc.date.available2023-02-09T10:39:30Z
dc.date.issued2021-01-08
dc.description.abstractUp to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. An observational, longitudinal, prospective cohort study was conducted. The study population comprised 38 patients with IBD aged Genes were differentially expressed in non-responders and responders (32 before initiation of treatment and 44 after two weeks, Log2FC (Fold change) >0.6 or 0.6 or Expression of the FCGR1A, FCGR1B, and GBP1 genes is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD.
dc.description.sponsorshipThis research was funded by Instituto de Salud Carlos III (grants numbers PI16/00559 and PI19/00792), Consejería de Educación y Deporte de la Comunidad de Madrid (grant number PEJ16/MED/AI-1260), and by the Gregorio Marañón Health Research Institute (grant number PRE2018-2). The study was cofunded by European Regional Develompment Funds (FEDER) from the European Commission, “A way of making Europe”.
dc.description.versionSi
dc.identifier.citationSalvador-Martín S, Kaczmarczyk B, Álvarez R, Navas-López VM, Gallego-Fernández C, Moreno-Álvarez A, et al. Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease. Pharmaceutics. 2021 Jan 8;13(1):77
dc.identifier.doi10.3390/pharmaceutics13010077
dc.identifier.issn1999-4923
dc.identifier.pmcPMC7830359
dc.identifier.pmid33429950
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830359/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/1999-4923/13/1/77/pdf?version=1610447336
dc.identifier.urihttp://hdl.handle.net/10668/16953
dc.issue.number1
dc.journal.titlePharmaceutics
dc.journal.titleabbreviationPharmaceutics
dc.language.isoen
dc.organizationHospital Universitario Puerta del Mar
dc.organizationHospital Universitario Reina Sofía
dc.organizationHospital Universitario Regional de Málaga
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.organizationÁrea de Gestión Sanitaria Sur de Sevilla
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationHospital Universitario Virgen Macarena
dc.organizationAGS - Sur de Sevilla
dc.provenanceRealizada la curación de contenido 20/02/2025
dc.publisherMDPI
dc.pubmedtypeJournal Article
dc.relation.projectIDPI16/00559
dc.relation.projectIDPI19/00792
dc.relation.projectIDPEJ16/MED/AI-1260
dc.relation.projectIDPRE2018-2
dc.relation.publisherversionhttps://www.mdpi.com/resolver?pii=pharmaceutics13010077
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCrohn disease
dc.subjectAdalimumab
dc.subjectBiomarker
dc.subjectGene expression
dc.subjectInflammatory bowel disease
dc.subjectInfliximab
dc.subjectUlcerative colitis
dc.subjectÁrea de Gestión Sanitaria Sur de Sevilla
dc.subject.decsGenes
dc.subject.decsFactor de necrosis tumoral alfa
dc.subject.decsAnciano
dc.subject.decsBiomarcadores
dc.subject.decsEstudios de cohortes
dc.subject.decsEnfermedades inflamatorias del intestino
dc.subject.meshGenes
dc.subject.meshTumor Necrosis Factor-alpha
dc.subject.meshCohort Studies
dc.subject.meshPharmaceutical Preparations
dc.subject.meshBiomarkers
dc.subject.meshInflammatory Bowel Diseases
dc.titleWhole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number13
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
PMC7830359.pdf
Size:
4.75 MB
Format:
Adobe Portable Document Format
Download
No Thumbnail Available
Name:
Salvador-Martin_Whole_MaterialSuplementario.pdf
Size:
467.68 KB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Regional Universitario de Málaga
Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
SAS - Hospital Universitario Puerta del Mar
SAS - Hospital Universitario Reina Sofía
SAS - Hospital Universitario Virgen de Valme
SAS - Hospital Universitario Virgen del Rocío
Load more

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía